SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.

Otros idiomas Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Acciones

6990

CNE1000062J1

Biotecnología e investigación médica

Mercado cerrado - Hong Kong S.E. Otros sitios de cotización 10:08:11 17/07/2026			Variación 5 días	Varia. 1 de enero.
486,40 ^HKD	-6,91 %		-5,83 %	+24,02 %

16/07	El fármaco de HBM Holdings contra el asma recibe el visto bueno en China	MT
15/07	Sichuan Kelun-Biotech Biopharmaceutical y Harbour Biomed reciben la aprobación de la NMPA para el ensayo clínico de SKB575/HBM7575 contra el asma	CI

Otros idiomas

16/07	HBM Holdings's Asthma Drug Candidate Secures China's Approval
15/07	Sichuan Kelun-Biotech Biopharmaceutical and Harbour Biomed Receive Nmpa Approval of Ind Application for Skb575/Hbm7575 for the Treatment of Asthma
15/07	Harbour BioMed And Kelun-Biotech Receive NMPA Approval Of IND Application For HBM7575/SKB575 For The Treatment Of Asthma
15/07	Sichuan Kelun-Biotech Biopharmaceutical Announces Phase III Study Of Sacituzumab Tirumotecan In Combination With Pembrolizumab As First-Line Treatment For PD-L1-Negative Non-Squamous NSCLC Meets Primary Endpoint
15/07	Kelun-Biotech's Lung Cancer Drug Trial Meets Primary Endpoint
15/07	Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
15/07	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Reports Primary Endpoint Met for Phase 3 Study of Sacituzumab Tirumotecan (SAC-TMT) in Combination with Pembrolizumab as First-Line Treatment of Pd-L1-Negative Locally Advanced or Metastatic Non-Squamous NSCLC
08/07	Sichuan Kelun-Biotech Seeks HK$2.7 Billion via Share Placement
01/07	Sichuan Kelun-Biotech Subscribes to Wealth Management Products
22/06	Sichuan Kelun-Biotech Biopharmaceutical Announces Translational Research Results And Clinical Development Of Sacituzumab Tirumotecan (Sac-TMT) In Combination With Osimertinib For EGFR-Mutant NSCLC
12/06	Sichuan Kelun-Biotech Receives Nearly 603 Million Yuan From MediLink
03/06	Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
31/05	Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
30/05	Sichuan Kelun-Biotech Biopharmaceutical Presents Results of Phase III Optitrop-Lung05 Study of Sacituzumab Tirumotecan in Combination with Pembrolizumab as First-Line Treatment for Pd-L1 Tps=1% Non-Small Cell Lung Cancer
30/05	Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
30/05	Sichuan Kelun-Biotech Biopharmaceutical Presents Pivotal Phase Ii Data for Lunbotinib Fumarate in Ret Fusion-Positive Nsclc
22/05	Kelun Biotech to Present Study Results of Cancer Drugs at American Oncology Meeting
22/05	Ellipses Pharma and Kelun-Biotech to Present Pivotal Trial Data for EP0031 in Ret-Fusion Positive Non-Small Cell Lung Cancer at ASCO 2026
22/05	Sichuan Kelun-Biotech Biopharmaceutical says NDA accepted for review by NMPA
22/05	Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
22/05	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Presents Two Registrational Studies At ASCO 2026
21/05	Kelun-Biotech's sac-TMT + pembrolizumab improves survival in late-stage China trial
21/05	Kelun, Merck's lung cancer combo improves survival in late-stage China trial
21/05	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Phase III Trial Results Of Sacituzumab Tirumotecan As First-Line Treatment For Advanced Triple-Negative Breast Cancer
18/05	Merck's drug helps uterine cancer patients live longer in late-stage trial